|
BACKGROUND AND PURPOSE : Castleman 's disease is a rare lymphoproliferative disease , also known as vascular follicular lymphoid hyperplasia or giant lymph node hyperplasia , involving the lymph nodes throughout the body , occur in the mediastinal and abdominal within . This paper reports the five cases of abdominal Castleman 's disease , and to explore the clinical features of Castleman 's disease , diagnostic methods , treatment options and prognosis . Methods : Retrospective analysis of general surgery admitted in our hospital from January 1, 2006 to 2011, five cases were diagnosed as abdominal Castleman 's disease patient clinical data and the literature reviewed . Results: 5 patients , 2 males , 3 females , age of onset is 24 to 61 years old, the average age of onset was 48.6 years . 4 cases of physical examination found that patients with symptoms of abdominal discomfort , patients have a history of anemia , the remaining cases there was no significant family history of special history . CT showed low density round, due to homogeneous enhancement , clear boundary rich blood supply mass . 5 patients underwent surgical removal of tumor , pathological confirmed for Castleman 's disease , including 2 cases of hyaline vascular type , 3 cases of plasma cell type . After 5 patients were alive today . Conclusion : Castleman 's disease is very rare , due to the lack of specific clinical manifestations , imaging and laboratory test results , very easy to misdiagnose . At present , the lack of progress of the tumor markers of the disease , the gold standard for diagnosis is still lymph node biopsy . Localized Castleman 's disease can be surgically complete excision of the lesion and cure , and multicentric Castleman 's Disease surgery with little success , there is no uniform treatment programs , the mainstream follow the principles of treatment of other lymphoproliferative disorders , chemotherapy and radiotherapy, can significantly relieve symptoms , but the prognosis is still poor , such as immunomodulatory agents , monoclonal antibodies, antiviral treatment programs still need to a large number of clinical trials testing the efficacy .
|